Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

o had not responded to previous interferon-based treatment regimens.

"The final Phase 2b results suggest that the every-two-week dosing regimen of Albuferon halves the number of injections that are required with peginterferon alfa-2a, while providing at least comparable efficacy, comparable safety and the potential for less impairment of quality of life and daily activity," said Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany. "We are continuing the evaluation of the 900-mcg and 1200-mcg doses of Albuferon in larger populations in Phase 3 trials. We also conclude that monthly dosing of Albuferon deserves further evaluation."

In the open-label, multi-center, active-controlled Phase 2b trial, 458 treatment-naive patients with genotype 1 chronic hepatitis C were randomized to four treatment groups: Albuferon 900 mcg every two weeks, Albuferon 1200 mcg every two weeks, Albuferon 1200 mcg every four weeks, and peginterferon alfa-2a 180 mcg once a week. All patients received weight-based oral ribavirin daily. The trial included 48 weeks of treatment, and the primary efficacy endpoint was SVR, defined as undetectable viral load (HCV RNA<10 IU/mL) at 24 weeks following completion of treatment.

"Assuming that the Phase 2 results are confirmed in Phase 3, we believe that Albuferon could become the interferon of choice in combination regimens for the treatment of chronic hepatitis C," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "Both of our Phase 3 trials have completed enrollment ahead of schedule, and we expect to have Phase 3 data available by spring 2009 to support the filing of global marketing authorization applications by fall 2009."

Key Findings from the Phase 2b Study

Albuferon requires half the number of injections as peginterferon alfa-2a, and the final results of the Phase 2b study demonstrated that Albuferon provid
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Calif., Dec. 15 Dakim, Inc. and Alzheimer,s ... for Loved Ones, Brain Health Contest, designed to help ... of dementia and Alzheimer,s disease. All five winners will ... designed specifically to help seniors preserve their brain health ... in senior living communities across the country. ...
(Date:12/15/2009)... --A Harvard medical expert internationally recognized as a ... Tour,s decision last month to suspend Doug Barron ... as having the medical condition hypogonadism ... "unreasonable, unfair and discriminatory." ,, Hypogonadism ... levels, often referred to informally as Low ...
(Date:12/15/2009)... Dec. 15 Today,s New ... "Plan for Kidney Drugs Spurs Division," illustrates an ... in kidney patients continuing to be deprived of ... Medicare program limit. ,, As Congress is poised ... preserve the lives of transplant kidney recipients, behind-the-scenes ...
Breaking Medicine Technology:5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Congressman Fattah Supports Legislation to Address More Funds for Pancreatic Cancer Research 60857 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 2Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 3Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 1Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 2
... and NYSE: SNY ) announced today that the ... in favor of the approval of Multaq(R) by the U.S. ... atrial fibrillation (AF). As demonstrated in the ATHENA trial, ... a clinical study a significant reduction in morbidity and mortality ...
... Alternext: ULU) announced that clinical evidence on ... the use of its patented Nanoflex(TM) Technology for Therapeutic ... Meeting in Los Angeles, California March 19-21. The ... on display during the meeting.Clinical evidence will be presented ...
Other Medicine Technology:FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone) 2FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone) 3ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:12/16/2009)... ( http://www.sermo.com ), the world,s largest online community ... new Sermo Vitals Report titled " Diabetes: MD ... physician dialog about diabetes over a one-year period ... of topics, including the therapies physicians discuss most ... on issues related to diabetes. ,, Leveraging ...
(Date:12/16/2009)... access to patient information could improve care, but ... 16 (HealthDay News) -- U.S. physicians support the ... exist about privacy problems, two new studies show. ... practice and specialist doctors in Massachusetts found that ... would improve patient quality of care, 70 percent ...
(Date:12/16/2009)... 14, 2009) Unisense FertiliTech A/S has received a further 1.6 million ... of the EmbryoScope™ Embryo Monitoring System in order to meet the ... invested by LD Pensions and Unisense A/S that continue to own ... ... Denmark (PRWEB) December 16, 2009 -- Unisense FertiliTech A/S has received ...
(Date:12/16/2009)... a bachelor degree, an individual can begin working and become ... ... (Vocus) December 16, 2009 -- According to " Measuring ... by the National Center for Public Policy and Higher Education, ... sectors of the economy.”¹ Since 1982, the national price of ...
(Date:12/16/2009)... Hair Shake in all of the Florida Whole Foods store. ... ... Larry Shapiro, hair transplant and hair loss physician , is pleased ... Hair Whey Protein Shake. Dr. Shapiro developed the all natural growth-hormone ... programs, working out and muscle building., , , , ,The Whole Foods ...
Breaking Medicine News(10 mins):Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 2Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 3Health News:Pros and Cons of Electronic Medical Records Weighed 2Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 3Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 5Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2
... Broad-ranging Report Concludes that Increased Resources Are An Essential ... ... food supply,is at risk, as are the regulatory systems that oversee the ... Board,in a report to be presented today. The subcommittee attributes the,deficiencies to ...
... 4, 2007 In a new evidence-based paper, the ... the United States and 12 other industrialized countries and ... political and social culture of the United States to ... universal health insurance coverage for all Americans. , As ...
... for Quality Long-Term Care Recommendations, WASHINGTON, Dec. ... the National Commission for Quality Long-Term Care,for its ... among policymakers,especially this year,s Presidential candidates. We urge ... the long-term care,challenges our nation faces and to ...
... Corporation,(Nasdaq: HSKA ) today announced it will ... December 6, 2007 at the Grand Hyatt Denver, ... scheduled to begin at 5:05,p.m. Mountain Time., ... Heska Corporation (NASDAQ: HSKA ) sells advanced ...
... Evaluates Best Drugs for 35 Conditions, YONKERS, ... needed between doctors and patients, especially,when it comes ... in the,January issue of Consumer Reports, in which ... initiative about drugs for 35 conditions including,Alzheimer,s disease, ...
... studies show strong link to recreational drugs as well. ... U.S. studies of gay and bisexual men who know ... one-third have recently had unprotected intercourse. , In many ... other HIV-infected men -- a practice called "serosorting," where ...
Other Medicine News:Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 2Health News:Internists diagnose health-care system ills, show how to achieve universal coverage 2Health News:Internists diagnose health-care system ills, show how to achieve universal coverage 3Health News:Internists diagnose health-care system ills, show how to achieve universal coverage 4Health News:NCOA Commends Long Term Care Commission Report 2Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 2Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 3Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 2Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 3Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 4
For the qualitative detection of IgG/IgM antibodies to B. burgdorferi...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. All SheerVision ...
... Experience the finest surgical-quality loupes available ... the standard for innovative optical design, ... support. Delivering optimum performance with maximum ... choice for medical professionals worldwide. All ...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... optimum performance with maximum comfort, SheerVision ... medical professionals worldwide. All SheerVision loupes ...
Medicine Products: